IntelliPharmaCeutics Announces FDA Acceptance For Filing Of NDA For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain Post author:Sam Post published:February 2, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Axovant CEO David Hung Abruptly Exits, COO and Several Directors Also Resign February 11, 2018 Galectin Tanks as NASH Drug Flunks Phase IIb Trial December 4, 2017 Boston's InSpire MD Eyes $24.8 Million Series C Round January 25, 2017